Treatment of the hepatorenal syndrome and hyponatremia in cirrhosis - part II

Dan Med J. 2012 Jan;59(1):C4372.

Abstract

National guidelines for treatment of ascites, spontaneous bacterial peritonitis, hepatorenal syndrome, and hyponatremia have been approved by the Danish Society of Gastroenterology and Hepatology. Ascites develops in approximately 60% of patients with cirrhosis during a 10 year period and is frequently associated with complications that determine the course of the disease and the prognosis. These evidence-based guidelines are divided in two parts and consider definitions, pathophysiology, diagnostic aspects, treatment, and prophylaxis.

MeSH terms

  • Acute Kidney Injury / etiology
  • Acute Kidney Injury / physiopathology
  • Clinical Protocols / standards
  • Contraindications
  • Diuretics* / administration & dosage
  • Diuretics* / adverse effects
  • Evidence-Based Medicine / standards
  • Fluid Therapy* / adverse effects
  • Fluid Therapy* / methods
  • Fluid Therapy* / standards
  • Hepatorenal Syndrome / diagnosis
  • Hepatorenal Syndrome / etiology
  • Hepatorenal Syndrome / metabolism
  • Hepatorenal Syndrome / physiopathology
  • Hepatorenal Syndrome / therapy*
  • Humans
  • Hyponatremia / etiology
  • Hyponatremia / metabolism
  • Hyponatremia / physiopathology
  • Hyponatremia / therapy*
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / physiopathology
  • Lypressin / administration & dosage
  • Lypressin / adverse effects
  • Lypressin / analogs & derivatives*
  • Renal Insufficiency, Chronic / etiology
  • Renal Insufficiency, Chronic / physiopathology
  • Terlipressin
  • Vasoconstrictor Agents / administration & dosage
  • Vasoconstrictor Agents / adverse effects
  • Water-Electrolyte Imbalance / etiology
  • Water-Electrolyte Imbalance / physiopathology

Substances

  • Diuretics
  • Vasoconstrictor Agents
  • Lypressin
  • Terlipressin